169 related articles for article (PubMed ID: 33631119)
41. Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Puentes LN; Lengyel-Zhand Z; Reilly SW; Mach RH
Mol Neurobiol; 2021 Aug; 58(8):3641-3652. PubMed ID: 33788167
[TBL] [Abstract][Full Text] [Related]
42. [Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
Lai FF; Li J; Ji M; Zhou Q; Wang LY; Chen XG
Yao Xue Xue Bao; 2016 Jun; 51(6):907-12. PubMed ID: 29879343
[TBL] [Abstract][Full Text] [Related]
43. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Hombach-Klonisch S; Kalantari F; Medapati MR; Natarajan S; Krishnan SN; Kumar-Kanojia A; Thanasupawat T; Begum F; Xu FY; Hatch GM; Los M; Klonisch T
Mol Oncol; 2019 Feb; 13(2):153-170. PubMed ID: 30289618
[TBL] [Abstract][Full Text] [Related]
44. Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300.
Das C; Dash SR; Sinha S; Paul S; Das B; Bhal S; Sethy C; Kundu CN
Med Oncol; 2023 Nov; 40(12):351. PubMed ID: 37940725
[TBL] [Abstract][Full Text] [Related]
45. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
46. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
[TBL] [Abstract][Full Text] [Related]
47. The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.
Lakatos P; Hegedűs C; Salazar Ayestarán N; Juarranz Á; Kövér KE; Szabó É; Virág L
Mutat Res; 2016 Aug; 790():31-40. PubMed ID: 27427773
[TBL] [Abstract][Full Text] [Related]
48. Poly-ADP-ribose polymerase inhibition enhances ischemic and diabetic wound healing by promoting angiogenesis.
Zhou X; Patel D; Sen S; Shanmugam V; Sidawy A; Mishra L; Nguyen BN
J Vasc Surg; 2017 Apr; 65(4):1161-1169. PubMed ID: 27288104
[TBL] [Abstract][Full Text] [Related]
49. PARP Inhibition Prevents Ethanol-Induced Neuroinflammatory Signaling and Neurodegeneration in Rat Adult-Age Brain Slice Cultures.
Tajuddin N; Kim HY; Collins MA
J Pharmacol Exp Ther; 2018 Apr; 365(1):117-126. PubMed ID: 29339456
[TBL] [Abstract][Full Text] [Related]
50. PJ34 Protects Photoreceptors from Cell Death by Inhibiting PARP-1 Induced Parthanatos after Experimental Retinal Detachment.
Dong K; Yan Y; Lu L; Wang Y; Li J; Zhang M; Ding J
Curr Eye Res; 2021 Jan; 46(1):115-121. PubMed ID: 32478624
[TBL] [Abstract][Full Text] [Related]
51. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
52. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
53. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
[TBL] [Abstract][Full Text] [Related]
54. Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes.
Saha LK; Murai Y; Saha S; Jo U; Tsuda M; Takeda S; Pommier Y
Nucleic Acids Res; 2021 Oct; 49(18):10493-10506. PubMed ID: 34551432
[TBL] [Abstract][Full Text] [Related]
55. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P
Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465
[TBL] [Abstract][Full Text] [Related]
56. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
Palve V; Knezevic CE; Bejan DS; Luo Y; Li X; Novakova S; Welsh EA; Fang B; Kinose F; Haura EB; Monteiro AN; Koomen JM; Cohen MS; Lawrence HR; Rix U
Cell Chem Biol; 2022 Feb; 29(2):202-214.e7. PubMed ID: 34329582
[TBL] [Abstract][Full Text] [Related]
57. PARP inhibition suppresses topoisomerase 1 poisoning induced Caspase-3 dependent cell death in zebrafish embryos.
Tsikarishvili S; Karapetian M; Kulikova N; Zaalishvili G
Biochem Biophys Res Commun; 2021 Apr; 550():166-170. PubMed ID: 33706100
[TBL] [Abstract][Full Text] [Related]
58. PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis.
Wu J; Xiao S; Yuan M; Li Q; Xiao G; Wu W; Ouyang Y; Huang L; Yao C
Mol Med Rep; 2019 Jan; 19(1):75-84. PubMed ID: 30431088
[TBL] [Abstract][Full Text] [Related]
59. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
60. Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration.
Sahaboglu A; Barth M; Secer E; Amo EM; Urtti A; Arsenijevic Y; Zrenner E; Paquet-Durand F
Sci Rep; 2016 Dec; 6():39537. PubMed ID: 28004814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
